Seres Therapeutics, Inc. (MCRB) stock
MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.41+0.00 (0.00%)
Close on Nov 17, 2026Market cap $14.02MP/E –Yield –
Seres Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Seres Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -1192.9%. For fiscal 2025 it was 721.9%, against -3509.5% the year before. The highest annual figure on record is 721.9% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 721.9% | +4231.4 |
| FY2022 | Dec 31, 2022 | -3509.5% | −3464.2 |
| FY2021 | Dec 31, 2021 | -45.2% | +223.1 |
| FY2020 | Dec 31, 2020 | -268.3% | −64.7 |
| FY2019 | Dec 31, 2019 | -203.7% | +146.3 |
| FY2018 | Dec 31, 2018 | -350.0% | −71.6 |
| FY2017 | Dec 31, 2017 | -278.4% | +142.3 |
| FY2016 | Dec 31, 2016 | -420.7% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 622.4% | +65072.4 |
| Q1 FY2026 | Mar 31, 2026 | -5562.3% | +9874.5 |
| Q4 FY2025 | Dec 31, 2025 | -3501.1% | −3537.9 |
| Q3 FY2025 | Sep 30, 2025 | 2337.3% | +9393.3 |
| Q4 FY2023 | Dec 31, 2023 | -64450.0% | −62707.8 |
| Q3 FY2023 | Sep 30, 2023 | -15436.8% | −10113.2 |
| Q2 FY2023 | Jun 30, 2023 | 36.8% | +3829.4 |
| Q4 FY2022 | Dec 31, 2022 | -7056.0% | −6363.6 |
| Q3 FY2022 | Sep 30, 2022 | -1742.2% | −1796.0 |
| Q2 FY2022 | Jun 30, 2022 | -5323.6% | −4405.3 |
| Q1 FY2022 | Mar 31, 2022 | -3792.6% | −3172.4 |
| Q4 FY2021 | Dec 31, 2021 | -692.4% | −588.5 |
| Q3 FY2021 | Sep 30, 2021 | 53.8% | +2190.7 |
| Q2 FY2021 | Jun 30, 2021 | -918.3% | −575.6 |
| Q1 FY2021 | Mar 31, 2021 | -620.2% | −377.5 |
| Q4 FY2020 | Dec 31, 2020 | -103.9% | +142.4 |
| Q3 FY2020 | Sep 30, 2020 | -2136.9% | −1903.5 |
| Q2 FY2020 | Jun 30, 2020 | -342.7% | −256.8 |
| Q1 FY2020 | Mar 31, 2020 | -242.8% | +89.6 |
| Q4 FY2019 | Dec 31, 2019 | -246.4% | −46.1 |
| Q3 FY2019 | Sep 30, 2019 | -233.4% | +9.0 |
| Q2 FY2019 | Jun 30, 2019 | -85.9% | +516.6 |
| Q1 FY2019 | Mar 31, 2019 | -332.4% | +370.7 |
| Q4 FY2018 | Dec 31, 2018 | -200.3% | +747.1 |
| Q3 FY2018 | Sep 30, 2018 | -242.4% | −212.3 |
| Q2 FY2018 | Jun 30, 2018 | -602.5% | +327.1 |
| Q1 FY2018 | Mar 31, 2018 | -703.1% | +141.8 |
| Q4 FY2017 | Dec 31, 2017 | -947.4% | −114.9 |
| Q3 FY2017 | Sep 30, 2017 | -30.1% | +113.5 |
| Q2 FY2017 | Jun 30, 2017 | -929.6% | – |
| Q1 FY2017 | Mar 31, 2017 | -844.9% | – |
| Q4 FY2016 | Dec 31, 2016 | -832.5% | – |
| Q3 FY2016 | Sep 30, 2016 | -143.6% | – |
See a number that looks wrong?